Finch Therapeutics Group, Inc. Stock News

During the last session, Finch Therapeutics Group Inc. (NASDAQ:FNCH)s traded shares were 0.51 million. At the end of the trading day, the stocks price was $8.95, reflecting an intraday loss of -8.11% or -$0.79. The 52-week high for the FNCH share is $22.50, that puts it down -151.4 from that peak though still a striking Finch Therapeutics Group Inc. (NASDAQ: FNCH) Continues To Thrive In 2021, As Its Stock Is Down -58.02% Year-To-Date Read More »

Finch Therapeutics Group, Inc. (NASDAQ:FNCH)s share price was up 5% during trading on Friday . The company traded as high as $15.58 and last traded at $15.24. Approximately 3,554 shares changed hands during trading, a decline of 96% from the average daily volume of 84,918 shares. The stock had previously closed at $14.51. Separately, Zacks []

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) traded up 5% during mid-day trading on Friday . The stock traded as high as $15.58 and last traded at $15.24. 3,554 shares traded hands during trading, a decline of 96% from the average session volume of 84,918 shares. The stock had previously closed at $14.51. Separately, Zacks Investment Research []

Finch Therapeutics Group, Inc. gapped down before the market opened on Wednesday. The stock had previously closed at $16.62, but opened at $16.24. Finch Therapeutics Group

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) gapped down before the market opened on Wednesday . The stock had previously closed at $16.62, but opened at $16.24. Finch Therapeutics Group shares last traded at $16.33, with a volume of 40 shares traded. Separately, Zacks Investment Research raised shares of Finch Therapeutics Group from a sell rating to [] The post Finch Therapeutics Group (NASDAQ:FNCH) Shares Gap Down to $16.62 appeared first on ETF Daily News .

Finch Therapeutics Group, Inc. (NASDAQ:FNCH)s share price gapped up prior to trading on Wednesday . The stock had previously closed at $13.54, but opened at $14.15. Finch Therapeutics Group shares last traded at $14.47, with a volume of 1,167 shares trading hands. Separately, Zacks Investment Research upgraded Finch Therapeutics Group from a sell rating to []

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) was the recipient of a large drop in short interest in October. As of October 29th, there was short interest totalling 187,900 shares, a drop of 19.1% from the October 14th total of 232,200 shares. Currently, 1.1% of the companys shares are sold short. Based on an average trading volume []

First Midwest Bank Trust Division acquired a new stake in Finch Therapeutics Group, Inc. (NASDAQ:FNCH) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 26,344 shares of the companys stock, valued at approximately $342,000. First Midwest Bank Trust Division owned approximately 0.06% []

Geode Capital Management LLC purchased a new stake in shares of Finch Therapeutics Group, Inc. (NASDAQ:FNCH) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 140,521 shares of the companys stock, valued at approximately $1,977,000. A number of other hedge funds have also made []

Related Stocks: ESGE , AAPL , MSFT , EEM , JPM , SBUX , IAU , FNCH , NOBL , BX , DGRO , OKE , VWO , VEA , VNQ , VTI , VOO , BND ,

Finch Therapeutics Group Inc (NASDAQ: FNCH) announced positive topline results from PRISM-EXT, an open-label extension of the PRISM3 Phase 2 trial evaluating CP101 to prevent recurrent C. difficile

SOMERVILLE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveragin

SOMERVILLE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveragin

SOMERVILLE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveragi

SOMERVILLE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveragin